(NBIX) Neurocrine Biosciences, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(NBIX) Neurocrine Biosciences, Inc. Complete Analysis Pack
Download Your Competitive Advantage
This Neurocrine Biosciences, Inc. BCG Matrix helps you understand how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
INGREZZA: 2 approved indications
INGREZZA is Neurocrine Biosciences, Inc.'s main revenue engine and its only major commercial star in the BCG matrix, with 2 approved uses: tardive dyskinesia and Huntington's disease chorea. In 2024, INGREZZA net sales reached $2.0 billion, showing strong VMAT2-leader demand. Its upside still hinges on label expansion and deeper share gains.
Tardive dyskinesia franchise: market leader
INGREZZA’s tardive dyskinesia franchise is still Neurocrine Biosciences, Inc.’s core market, and it remains the Company’s largest commercial engine. In FY2025, INGREZZA continued to drive most of the Company’s revenue, with sales above $2.5 billion and total Company revenue above $2.7 billion. That mix of dominant share in specialty CNS and continued growth support fits a Star.
Huntington’s disease chorea use: 2023 expansion
Neurocrine Biosciences, Inc. gained a second growth leg in 2023 when Ingrezza was approved for Huntington’s disease chorea, expanding beyond tardive dyskinesia. Huntington’s disease affects about 30,000 people in the U.S. and has no cure, so the new label opens a durable adjacent market. That extra use extends the commercial runway and fits a Star: high growth, still gaining share.
VMAT2 inhibitor leadership
Neurocrine Biosciences, Inc. is one of the key branded leaders in VMAT2 inhibition, with Ingrezza still the category anchor. That position gives it strong physician familiarity and clear scientific differentiation, which supports share as the brand scales. In FY2025, the franchise remained a multibillion-dollar revenue driver, reinforcing this as a Star in the BCG matrix.
- Leading branded VMAT2 position
- Strong doctor familiarity
- Scale supports durable share
Neurocrine commercial engine: one-brand concentration
Neurocrine Biosciences, Inc. is still a one-brand story: INGREZZA drove about $2.1 billion of the company’s roughly $2.4 billion 2024 product sales, making it the clear high-share growth asset in the marketed portfolio. That concentration means the commercial engine is built on one scaled brand, plus a small set of newer follow-ons like CRENESSITY.
- INGREZZA is the main cash engine.
- Follow-ons are still early-scale.
- One-brand mix fits a Star profile.
INGREZZA Powers Neurocrine’s $2.7B+ Revenue Surge
INGREZZA is Neurocrine Biosciences, Inc.'s Star: in FY2025, sales topped $2.5 billion, and Company revenue topped $2.7 billion. With approved uses in tardive dyskinesia and Huntington’s disease chorea, it keeps a dominant share in VMAT2 therapy and remains the main growth engine.
| Metric | FY2025 |
|---|---|
| INGREZZA sales | $2.5B+ |
| Company revenue | $2.7B+ |
| Key role | Star asset |
What is included in the product
Detailed Word Document
Neurocrine’s BCG Matrix maps its drugs by growth and market share, highlighting Stars, Cash Cows, Question Marks, and Dogs.
Editable Excel File
Covers Neurocrine Biosciences, Inc. BCG Matrix pain points in a clean, C-level ready layout.
Reference Sources
Provides a clear source trail for Neurocrine Biosciences, helping stakeholders verify key claims fast and make more confident decisions.
Cash Cows
ORILISSA: endometriosis pain
ORILISSA, approved by the U.S. FDA in 2018, is Neurocrine Biosciences' oral therapy for moderate to severe endometriosis pain and is now an established brand, not a launch asset. With endometriosis affecting about 1 in 10 women of reproductive age, it can act like a cash cow if Neurocrine keeps share in this mature specialty niche. Its role is steady, but growth depends on keeping prescriber loyalty and payer access strong.
ORIAHNN: uterine fibroid bleeding
ORIAHNN is approved for heavy menstrual bleeding linked to uterine fibroids in premenopausal women, so it serves a tight, recurring prescription niche for Neurocrine Biosciences, Inc. Treatment is limited to 24 months because of bone loss risk, but that still supports repeat use and steady refill demand. In BCG terms, that profile fits a low-growth Cash Cow: narrow market, durable sales, and reliable cash flow.
ONGENTYS: Parkinson’s adjunct therapy
In 2025, ONGENTYS remained a mature adjunct therapy for Parkinson’s disease, used with levodopa plus a DOPA decarboxylase inhibitor to reduce off-time in chronic patients. Because the addressable population is ongoing and repeat-use is long term, stable share can support cash-cow economics. If growth slows but refills stay steady, margin-rich sales can keep funding Neurocrine Biosciences, Inc.'s pipeline.
Women’s health franchise: 2 approved brands
ORILISSA and ORIAHNN make up Neurocrine Biosciences, Inc.’s women’s health cash cow: two FDA-approved, oral, specialist-prescribed brands with steady, repeatable demand. This franchise is far smaller than INGREZZA, but its mature position helps support dependable cash flow and lowers concentration risk. In 2025, Neurocrine Biosciences, Inc. still carried this base as part of a $2B-plus revenue mix.
- 2 approved brands: ORILISSA, ORIAHNN
- Oral and specialist-prescribed
- Stable, lower-growth cash source
- Supports Neurocrine Biosciences, Inc. cash flow
Approved portfolio base: recurring sales
Neurocrine Biosciences had 4 marketed medicines in 2025, led by Ingrezza, so it already has a repeat-sales base outside the pipeline. Mature approved brands need far less launch spend than new drugs, which supports steadier cash flow and fits BCG cash cow logic. That base helps fund R&D while sales keep recurring.
- 4 marketed medicines in 2025
- Lower launch spend than pipeline assets
- Recurring sales support cash flow
Neurocrine’s Cash Cows: Steady Revenue from Mature Brands
Neurocrine Biosciences, Inc.'s cash cows are its mature women’s health and Parkinson’s brands: ORILISSA, ORIAHNN, and ONGENTYS. These FDA-approved, specialist-prescribed drugs have recurring demand and low launch spend, so they generate steady cash rather than fast growth. In 2025, Neurocrine Biosciences, Inc. had 4 marketed medicines and more than $2B in revenue, which supports this BCG Cash Cow profile.
| Asset | Cash cow fit | Why it matters |
|---|---|---|
| ORILISSA | High | Mature, repeat use |
| ORIAHNN | High | Niche, steady demand |
| ONGENTYS | Medium | Recurring Parkinson's use |
Get Your Copy
Neurocrine Biosciences, Inc. Reference Sources
The Neurocrine Biosciences, Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No sample pages, no watermarks, and no hidden edits—just the full, finalized report. Once purchased, it’s ready to download, review, and use right away.
Dogs
Heptares Therapeutics alliance
Heptares Therapeutics alliance is a partnered R&D program, not a marketed Neurocrine Biosciences, Inc. product. As of end-2025, it has 0 direct company-level sales, so its BCG profile is a low-share, non-core Dog unless it moves into a clear launch. Value is still tied to clinical success, not commercial cash flow.
Takeda Pharmaceutical alliance
The Takeda Pharmaceutical alliance is partner-dependent, so Neurocrine Biosciences, Inc. does not fully control pricing, promotion, or end-market access. That makes the unit a weak stand-alone asset in a BCG Dogs view, with limited direct share capture. As of the latest reported period, the business still depends on Takeda’s commercial execution rather than owned-brand scale.
Idorsia Pharmaceuticals collaboration
Idorsia Pharmaceuticals collaboration is still a partnership asset, not a Neurocrine Biosciences, Inc. marketed product, so it has 0 direct commercial sales today. That means no material Neurocrine franchise is visible from this tie-up alone. In BCG terms, it fits low share and low growth, with value tied to future pipeline success, not current revenue.
Xenon and Voyager collaborations
Xenon and Voyager are development collaborations, not sales engines, so they fit the Dogs slot in Neurocrine Biosciences, Inc. BCG Matrix. They add science value, but there is no reported commercial share or product revenue from these programs yet, while Neurocrine’s sales still come mainly from Ingrezza.
- Pipeline value, not market share
- No direct sales contribution yet
- Weak-share bucket until launch
BIAL, Mitsubishi Tanabe, AbbVie alliances
BIAL, Mitsubishi Tanabe, and AbbVie are partner-led deals, mostly for development or regional rights, so they do not drive Neurocrine Biosciences, Inc.'s 2025 sales mix the way INGREZZA does, which still generated the vast bulk of revenue. With limited direct commercial scale and no clear stand-alone profit engine, they fit the Dog quadrant more than growth buckets.
- Partner-led, not core commercial
- Regional rights, narrow upside
- FY2025 sales remain INGREZZA-led
- Low strategic weight in BCG
Neurocrine’s Dogs: Pipeline Value, No 2025 Sales
Dogs in Neurocrine Biosciences, Inc. are partner-led programs with no direct 2025 sales, so they sit in the low-share, low-cash bucket. INGREZZA still drove most revenue, at about $2.2 billion in FY2025, while these alliances add pipeline value only if they convert to marketed products.
| Asset | 2025 view | BCG fit |
|---|---|---|
| Heptares, Takeda, Idorsia, Xenon, Voyager, BIAL, Mitsubishi Tanabe, AbbVie | 0 direct sales | Dog |
Question Marks
NBI-921352: focal epilepsy
NBI-921352 is an investigational asset for pediatric and adult focal epilepsy, a large market serving about 50 million people worldwide and roughly 3.4 million in the United States. Neurocrine Biosciences, Inc. has no approved epilepsy revenue yet, so this sits as a Question Mark: high upside if trials and approval land, but clear execution risk. In BCG terms, it is growth potential without current market share.
NBI-827104: rare pediatric epilepsy
NBI-827104 sits in the Question Mark bucket because it targets rare pediatric epilepsy and essential tremor, both specialty neurology spaces with real upside if trial data hold up. The asset still has low share because it is in development, so it has no commercial sales yet. If Neurocrine Biosciences, Inc. shows strong efficacy and safety, the program could move from optionality to a growth driver.
NBI-1065845: major depressive disorder
NBI-1065845 fits the Question Mark slot in Neurocrine Biosciences, Inc.'s BCG Matrix: it targets major depressive disorder, a global market affecting over 280 million people, but it is still pre-commercial. The asset has high upside if it works, yet it has no sales base today, so cash burn and trial risk remain the key watch points. In a 2025/2026 view, it is an option on a large CNS market, not a revenue driver.
NBI-1065846: anhedonia in MDD
NBI-1065846 targets anhedonia in major depressive disorder, a distinct symptom linked to poor function and high unmet need. If Neurocrine Biosciences, Inc. proves clear efficacy, the program could move into a high-value niche. Right now it still has low share and sits in the Question Mark bucket.
- High unmet need
- Possible differentiated psychiatric use
- Low current pipeline share
NBI-118568: schizophrenia
NBI-118568 is still in development for schizophrenia, so Neurocrine Biosciences, Inc. has no sales base here yet. Schizophrenia affects about 24 million people worldwide, and the market is crowded with entrenched players and high relapse risk, which makes entry hard. That keeps this asset a high-risk Question Mark in the BCG Matrix.
- Large unmet need
- No current market share
- High clinical and commercial risk
Neurocrine’s CNS Question Marks: High Upside, High Trial Risk
Neurocrine Biosciences, Inc.’s Question Marks are mostly pre-revenue CNS assets with big markets but no commercial share yet. NBI-921352, NBI-827104, NBI-1065845, NBI-1065846, and NBI-118568 could add value only if late-stage data and approvals land, so trial risk is still the main driver. In 2025/2026, they remain optionality plays, not cash engines.
| Asset | BCG view | Why |
|---|---|---|
| NBI-921352 | Question Mark | Epilepsy; no sales yet |
| NBI-118568 | Question Mark | Schizophrenia; low share |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.